Gemcitabine with Capecitabine effective against pancreatic cancer

Combination of two chemotherapy drugs has found to be effective in treating patients with pancreatic cancer compared to use of single drug. A combination of Gemcitabine and Capecitabine has been found to decrease the number of deaths due to pancreatic cancer.// Early and effective to pancreatic can...

Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer

... was extended in patients treated with Nexavar and capecitabine compared to patients receiving capecitabine and placebo. These results were statistically sign...lacebo twice daily, in addition to 1000 mg/m(2) of capecitabine twice daily for 14 days followed by a seven day re...

Fingerprints May Vanish With Cancer Drug

...27 (HealthDay News) -- The widely used cancer drug capecitabine can cause people to lose their fingerprints, which...re in Singapore, said he now advises people taking capecitabine to carry a doctor's letter when traveling. In a... experience of a 62-year-old cancer patient taking capecitabine who was held for four hours by U.S. immigration of...

Cancer drug causes patient to lose fingerprints and be detained by US immigration

...dose of capecitabine, an anti-metabolite drug. capecitabine is a common anti-cancer drug used in the treatment... concludes: "In summary, patients taking long-term capecitabine may have problems with regards to fingerprint iden... patients as Mr S who may benefit from maintenance capecitabine for disseminated malignancy. These patients should...

Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer

...rug Administration for cancer, although vinorelbine has not been approved for this particular treatment regimen in the U.S., the researchers say. capecitabine chemotherapy is not usually paired with trastuzumab because some studies had suggested it does not offer a synergistic, or additive, benefit. However,...

Triple drug combination is promising option to treat metastatic HER2+ breast cancer

...d Drug Administration for cancer, although vinorelbine has not been approved for this particular treatment regimen in the U.S., the researchers say. capecitabine chemotherapy is not usually paired with trastuzumab because some studies had suggested it does not offer a synergistic, or additive, benefit. However,...

Study shows chemotherapy improves survival among older breast cancer patients

...t cancer. But the study showed that patients who were randomly assigned to capecitabine were twice as likely to have a relapse, and at three-years after completing therapy, the rate of relapse-free survival was 68 percent in the capecitabine group versus 85 percent in the standard-chemotherapy group. ...

Chemotherapy Superior to New Drug for Early Breast Cancer

...ndard chemotherapy than they do with the oral drug capecitabine (Xeloda), a new study finds. "After three years...doing well, and 68 percent of people who received capecitabine were doing well," said lead researcher Dr. Hyman M...f Medicine . Because it has fewer side effects, capecitabine has been approved by the U.S. Food and Drug Admini...

Research Findings on Nine GlaxoSmithKline Cancer Compounds to be Presented at ASCO 2009

... Lapatinib, in combination with capecitabine, is authorized in 74 countries. On March 13, 2007, the U.S. FDA approved lapatinib in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2/ErbB2 and who have received prior therapy includ...

Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment

...offmann-La Roche Inc. in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for capecitabine Tablets, 150 mg and 500 mg, the generic version of Xeloda(R) Tablets, a chemotherapy treatment for breast and colorectal cancer. Mylan believes i...

Capecitabine in Medical Technology

Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine

- Phase II Results Published in the Journal of Clinical Oncology - NEW YORK, July 06, 2007 /PRNewswire-FirstCall/ -- Results from a Phase II study - which will be published in the August 10, 2007 issue of the Journal of Clinical Oncology (JCO) and are now available as an Early Release Article at <...

Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative

...-dose, long-term oral chemotherapy agents in adjuvant (i.e. follow-up) cancer treatment represents new and exciting territory for Karmanos scientists. capecitabine was the first FDA-approved oral chemotherapy treatment, gaining approval for human use in 1998. Since then, other oral cancer agents have been develop...

Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

... KRX-0401 + capecitabine More Than Doubles Time to Progression and Overall ...onse Rate as well as Extends Overall Survival vs. capecitabine + Placebo in Patients with 2nd or 3rd Line Metasta...ny's Akt-inhibitor for cancer, in combination with capecitabine as a treatment for advanced colon cancer. Abstrac...

Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

... KRX-0401 + capecitabine More Than Doubled Time to Progression and Overall ...onse Rate as well as Extended Overall Survival vs. capecitabine + Placebo in Patients with 2nd or 3rd Line Metasta...ny's Akt-inhibitor for cancer, in combination with capecitabine as a treatment for advanced colon cancer. Abstrac...

New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer

...gnificant improvement in Sunday 14th, al. for The recurrence-free survival (RFS) December Finnish Breast when capecitabine (X) is 11:45 hrs Cancer Group integrated into docetaxel (T) General 5-FU + epirubicin + cycl...

ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)

...f Medical Affairs on June 2, 2008. Historically, capecitabine (Xeloda(R)), a widely-used treatment for advanced ...recently published, Phase 3 clinical trials, where capecitabine was the approved therapy, demonstrated response rates of 14% for capecitabine alone compared with 35% for...

US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings

... eribulin mesylate in patients with locally advanced or metastatic breast cancer (MBC) previously treated with an anthracycline, taxane, and capecitabine -- Sasha Vukelja, M.D., Texas Oncology-Tyler: Phase II and Phase III study of the efficacy of nab-paclitaxel in patients with poor prognos...

New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens

...n. Women should be advised not to become pregnant when taking TYKERB. The most common adverse events (>20 percent) during treatment with TYKERB plus capecitabine were diarrhea, vomiting, nausea, fatigue, palmar-plantar erythrodysesthesia, and rash. Please see full prescribing information. Notes to edito...

Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting

...:00 PM 32A(1063) Phase II trial of paclitaxel June 2 poster poliglumex (PPX) with capecitabine (C) for metastatic breast cancer (MBC). For more information about the ASC...

Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting

...; results support clinical testing of this regimen in colorectal cancer patients. [See 2008 ASCO Proceedings I - An alternative preclinical regimen of capecitabine ( C ) enhances single agent & combination activity in a colorectal cancer xenograft model. (Lead Author: Kenneth Kolinsky)] Among ex-U.S. Xeloda abs...

Capecitabine in Biological News

Eribulin mesylate demonstrated anti-tumor activity in patients with advanced breast cancer

...efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer who had received an anthracycline, a taxane and capecitabine as prior therapy, and who were refractory to their last chemotherapy regimen, as documented by progression on or within six months of that therapy. ...

New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients

...taxel followed by four cycles of capecitabine. If capecitabine were to improve outcomes, we wanted to see how bes...t the scientists did find was that the addition of capecitabine to the chemotherapy regime produced more non-haema...itz. Given the lack of extra efficacy of adding capecitabine to docetaxel, and the additional toxicities that i...

Capecitabine in Biological Technology

GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases

Study Shows TYKERB Combination Reduced the Size of Brain Tumors Associated with HER2-Positive Breast Cancer SAN ANTONIO, Texas, Dec. 17 /PRNewswire/ -- GlaxoSmithKline announced today results from the extension arm of a Phase II study on its first-in-class, oral small molecul...

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

...ently, positive results were reported for the single agent use of perifosine in patients with advanced metastatic renal cancer and in combination with capecitabine for advanced metastatic colon cancer (placebo-controlled), as well as for perifosine in combination with bortezomib +/- dexamethasone in relapsed and ...

AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer

...ently, positive results were reported for the single agent use of perifosine in patients with advanced metastatic renal cancer and in combination with capecitabine for advanced metastatic colon cancer (placebo-controlled), as well as for perifosine in combination with bortezomib +/- dexamethasone in relapsed and ...

AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting

...2009 #4081: Randomized Phase 2 study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer. Lea...

Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology

...: #4081: Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer. ...

Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting

...al Cell Carcinoma: A Phase 2 Study of Sorafenib, Gemcitabine and Metronomic capecitabine in Patients with Advanced mRCC Joaquim Bellmunt, M.D., Chief... A Phase I Dose-Finding Study of Sorafenib in Combination with capecitabine and Cisplatin as a First-Line Treatment in Patients with Advanced Gastric C...

FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer

...so granted approval of IXEMPRA in combination with capecitabine for the treatment of patients with metastatic or l...PRA either as a monotherapy or in combination with capecitabine in patients with metastatic or locally advanced br...n combination with capecitabine in comparison with capecitabine as monotherapy. This trial included 752 patients w...

Gene-Expression Analysis of TP, DPD, and TS Using the LightCycler mRNA Quantification KitsPLUS

...rimidine treatment has led to the development of capecitabine (Xeloda), a fluoropyrimidine drug from Roche Pharmaceuticals. capecitabine is not cytotoxic unless it is activated to 5-FU ... capecitabine is preferentially activated and converted to 5-F...